Rumors Were True – Again: Abbott Did Try To Pull Out Of Alere Deal
This article was originally published in Clinica
Executive Summary
Alere confirmed analysts’ suspicions that Abbott Laboratories is reticent about its planned $5.8bn takeover of the embattled diagnostics company, but the deal appears to be back on track, for now.
You may also be interested in...
Alere Hit With Another Federal Subpoena, Casting More Doubt On Abbott Deal
The company says the matters under investigation are immaterial, but the stock market disagrees, taking about a billion dollars from embattled diagnostics company in under a half-hour.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.
New’s We’re Watching: J&J's Varipulse PFA Earns CE Mark; Labs Create Intravascular Robots; And More
Medtech Insight's News We're Watching highlights some recent business and R&D developments you may have missed. This week, Biosense Webster’s Varipulse PFA platform earned a CE mark; Biosense Webster also announced the start the pivotal IDE study of its Laminar left atrial appendage elimination system; the FDA approved Boston Scientific's Agent paclitaxel-coated balloon and cleared Medtronic's OsteoCool 2.0 bone ablation system; three papers in Science Robotics describe magnetically controlled vascular robots that could go places wires and catheters cannot.